Department of Clinical Research, Roche Products Limted, Welwyn Garden City, Hertfordshire.
Br J Clin Pharmacol. 1974 Apr;1(2):143-9. doi: 10.1111/j.1365-2125.1974.tb00223.x.
1 A new β-adrenoceptor blocking agent, Ro 3-4787, was administered orally to resting subjects. Peak levels of 106.2 ± 15.5 ng/ml were reached after 20 mg given in the fasting state. After intravenous administration, an inverse rectilinear relationship was shown between the log dose (2 mg-20 mg) and the heart rate during vigorous exercise on a bicycle ergometer. 2 A double-blind study in five normal subjects using 0.03 mg/kg and 0.15 mg/kg showed that propranolol and Ro 3-4787 were equally effective in reducing the exercise heart rate. There was an inverse correlation between the log plasma level before exercise and the heart rate during exercise for both drugs over the range studied.
一种新的β-肾上腺素受体阻滞剂，Ro 3-4787，在空腹状态下口服给予休息的受试者。在给予 20mg 后，达到 106.2±15.5ng/ml 的峰值水平。静脉给药后，在自行车测力计上剧烈运动期间，剂量（2mg-20mg）的对数与心率呈反直线关系。
在五名正常受试者中进行的一项双盲研究，使用 0.03mg/kg 和 0.15mg/kg 表明，普萘洛尔和 Ro 3-4787 在降低运动心率方面同样有效。在研究范围内，两种药物在运动前的对数血浆水平与运动期间的心率之间存在反比关系。
